What is the market's earnings forecast for PureCycle next quarter?

What factors drove the changes in PureCycle's revenue and profit?

What is the revenue and EPS growth rate for PureCycle year over year?

What guidance did PureCycle's management provide for the next earnings period?

Did PureCycle beat or miss consensus estimates last quarter?

What were the key takeaways from PureCycle's earnings call?

What is PureCycle's gross profit margin?

What does PureCycle do and what are its main business segments?

- **Operational Record-Breaking**: Ironton produced 7.2M lbs (3.3M lbs in September), Denver processed 9.4M lbs of feedstock.
- **Commercial Momentum**: 40-50M lbs annual demand from top applications, P&G trials for 2026, QSR lid shipments Q4.
- **Cost Optimization**: Co-product sales reduce feedstock costs by 20%, non-PP co-products sold at $0.20-$0.30/lb.
- **Global Expansion**: Thailand feedstock secured, EUR 40M EU grant for Antwerp, Gen 2 design on track.
- **Automotive Breakthrough**: VW bumper trial success, targeting 2026 automotive trials.

**【CEO Opening Remarks】**
- Announced Dr. Siri Jirapongphan's board appointment, bringing expertise in Southeast Asia and debt financing.
- Highlighted Q3 operational milestones: Ironton produced 7.2M lbs (3.3M lbs in September), Denver processed 9.4M lbs of feedstock.
- Expanded capacity with Denver's second shift and planned third shift, targeting 100M lbs annual capacity.
- Commercial progress: P&G trials for 2026, QSR coffee lid shipments in Q4, and 40-50M lbs annual demand from top applications.
- Advanced co-product optimization, selling non-PP co-products for $0.20-$0.30/lb, reducing feedstock costs by 20%.
- Global expansion updates: Thailand feedstock LOIs, Antwerp EU Innovation Fund grant (EUR 40M), and Gen 2 design completion in H1 2026.

**【CFO Financial Commentary】**
- Ended Q3 with $234M cash and $87M revenue bonds.
- Operational spend $37M, capital spend to increase in 2026.
- EUR 40M grant for Antwerp project, reducing capital requirements.
- Warrant exercise potential ($11.50/share) and nondilutive financing efforts.

**【Q&A Highlights】**
- **Co-product monetization**: Sold 20-30% of non-PP co-products, reducing costs by 20%.
- **Customer demand**: QSRs and P&G trials driving 40-50M lbs annual demand.
- **Thailand expansion**: Feedstock availability exceeds capacity, cost economics favorable.
- **Automotive progress**: VW bumper trial success, targeting 2026 automotive trials.
- **Regulatory compliance**: REACH certification enabling European sales, ISO 14001 in process.
- **Project timelines**: Ironton ramp to 60-70% capacity by end-2025, full nameplate in H2 2026.

PureCycle Technologies, Inc. (PCT) Q3 2025 Earnings Call Transcript

- **$300M Capital Raise Drives Global Expansion**: 1 billion pounds of capacity by 2030, with Thailand and Antwerp as key hubs.
- **Commercial Breakthroughs**: 17 post-trial applications, 5M lbs/year deal with Emerald, and first successful film trial.
- **Operational Excellence**: Ironton at 90% uptime, testing 14,000 lbs/hour, with 100M lbs/year compounding expansion.
- **Financial Strength**: $298M cash, EBITDA breakeven expected Q3/Q4 2025, and $4M annual cost savings from compounding.
- **Strategic Differentiation**: FDA-certified PCR resin, feedstock+ pricing, and Procter & Gamble exclusivity in key regions.

**【CEO Summary Section】**
- **Capital Raise and Expansion**: Secured $300 million capital raise to expand global capacity to 1 billion pounds by 2030, with initial focus on Thailand (low-cost, high ROIC) and Antwerp (European demand hub). Gen 2 design for larger facilities is underway.
- **Commercial Momentum**: 17 post-trial customer applications across FDA and non-FDA polypropylene, including 5 million pounds/year deal with Emerald Carpets. Serviceable addressable market expanded to 4.8 billion pounds.
- **Operational Progress**: Ironton Facility achieved 90% onstream time in Q2, produced 65 days consecutively, and tested at 14,000 lbs/hour. First successful film trial completed ahead of schedule, with 3 additional trials planned for Q3.
- **Strategic Initiatives**: Announced in-house compounding expansion to 100 million pounds/year, reducing costs by $4 million annually and improving logistics for large-volume customers.

**【CFO Financial Commentary】**
- **Liquidity**: Ended Q2 with $298 million cash, including $284 million unrestricted. Sold $10.5 million in revenue bonds, with $87 million remaining to support growth.
- **Spending**: Operational expenses $39 million (up from $37 million in Q1). Growth capital spend expected to increase gradually as projects progress.
- **Future Outlook**: Anticipate EBITDA breakeven for Ironton in Q3 and corporate breakeven in Q4/Q1 2026, driven by commercial ramp and cost optimization.

**【Q&A Key Highlights】**
- **Growth Strategy**: Thailand project ($1.50-$1.75 CapEx/lb) prioritized for speed and returns. Gen 2 design targeting $300+ million/lb capacity with improved cost structure.
- **Customer Dynamics**: 1 trial dropout in Q2, attrition rate <1%. Customers reserving 2026 capacity despite trials, with some requesting >5 million lbs/year.
- **Competitive Position**: Differentiated by FDA-certified PCR resin and compounding flexibility. Feedstock+ pricing model protects margins against mechanical recyclers.
- **Circularity Push**: Partnership with Emerald to create closed-loop supply chain, aligning with regulatory trends like California's 5% recycled content mandate.


PureCycle Technologies, Inc. (PCT) Q2 2025 Earnings Call Transcript

- **Revenue Milestone**: Q1 2025 marked PureCycle's first reported revenues, with 4.3M lb produced and 14M lb inventory.
- **Operational Excellence**: 90% onstream time in April, up from <30% a year ago, signaling Ironton reliability.
- **Product Innovation**: PureFive Choice compounds enable film (30-50% PCT blend) and fiber (50-50 blend) breakthroughs, with Bruckner BOPP film trial success.
- **Trial Growth**: 33 active trials (24 industrial-stage), with 13 in rigid packaging and auto OEM discussions.
- **Future Scale**: Planning 200-500M lb/year facilities, leveraging Ironton's 90% uptime and $37M/Q1 operational efficiency.
- **Financial Strategy**: Selling $85M revenue bonds to fund growth, targeting Ironton breakeven in Q3 and corporate breakeven in 2026.

**【CEO Key Highlights】**
- **First Revenue Achievement**: Generated initial revenues in Q1 2025, marking a historic milestone.
- **Operational Progress**: Achieved 90% onstream time in April, producing 4.3 million pounds of resin, with 14 million pounds in inventory.
- **Product Expansion**: Launched PureFive Choice, a compounded product line targeting film, fiber, and automotive applications, with successful trials at Bruckner (BOPP film) and Drake (fiber).
- **Trial Momentum**: 33 active trials (24 industrial-stage), including 13 in rigid packaging, with conversions to purchase orders.
- **Future Growth**: Planning larger-scale facilities (200-500M lb/year) leveraging Ironton learnings, with Augusta and international expansion in pipeline.

**【CFO Financial Update】**
- **Cash Position**: $37.5M cash on hand, including $22.5M unrestricted; raised $55M through private placements and revenue bonds.
- **Expenditures**: Q1 spend $37M, aligned with prior-year levels, driven by Augusta and Denver operations.
- **Liquidity Strategy**: Selling remaining $85M revenue bonds to support growth, targeting Ironton breakeven in Q3 and corporate breakeven in 2026.

**【Q&A Key Takeaways】**
- **Inventory Strategy**: Holding back 14M pounds for higher-value branded sales in H2 2025.
- **Film Market Breakthrough**: Bruckner trial success could unlock 30B lb/year BOPP film market, with trials expanding to end customers.
- **Pricing Model**: Moving toward feedstock-plus pricing, reflecting specialty product dynamics.
- **Capital Efficiency**: Future facilities to benefit from Ironton learnings, reducing CapEx and OpEx per pound.
- **Regulatory Tailwinds**: 2030 EU/Japan recycled content mandates driving auto and consumer goods demand for PCT materials.

PureCycle (PCT)-7 May 25-2025 Q1 Earnings call transcript

- **Commercial Breakthroughs**: 29 trials underway, 16 at industrial scale, with 250-500M lbs/year demand potential. Key wins with Drake (70M lbs) and Churchill (sports cups). 
- **Ironton Optimization**: Q4 production 3.6M lbs, 70% onstream time, near nameplate capacity. 
- **Capital Strength**: $33M Feb raise + $118M bonds provide ample liquidity. 
- ** Automotive Growth**: P&G exclusivity extended, 5 automotive trials, 30M lbs/year bumper facia opportunity. 
- **Global Expansion**: Augusta equipment secured, EU/Asia discussions active. 


**【CEO Summary Section】**
- **Commercial Momentum**: Q4 2024 highlighted successful customer trials across 29 applications, with 16 in industrial scale, representing 250-500M lbs/year potential demand. Key wins include Drake Extrusion (70M lbs/year PP) and Churchill Containers (sports souvenir cups). 
- **Ironton Plant Progress**: Q4 production reached 3.6M lbs, with max feed rate near nameplate capacity. Onstream time improved to 70% in December, driven by operational efficiency gains. 
- **Customer Expansion**: Procter & Gamble extended exclusivity agreement, entering 5 automotive applications. Automotive trials with Washington Penn for bumper facias show 30M lbs/year potential. 
- **Global Growth**: Secured $33M capital raise in Feb 2025, with $118M revenue bonds available. Augusta expansion equipment purchased, with EU and Asian opportunities in pipeline. 

**【CFO Financial Commentary】**
- **Liquidity**: Ended Q4 with $15.8M cash, raised $33M in Feb 2025. $118M revenue bonds expected to close in 2025. 
- **Cash Flow**: Q4 cash expenses $68M (including $36M capex). Projected monthly cash burn ~$9M, manageable with current liquidity. 
- **Unit Economics**: Maintain $1.36/lb sales price target. Variable costs optimized via Denver flake sorting and co-product sales ($0.22-0.55/lb). Ironton breakeven at 40-50% utilization, PCP at 80-90%. 

**【Q&A Highlights】**
- **Production Strategy**: Pacing Ironton production to match customer trials, avoiding inventory buildup. 12,500 lbs/hour max rate achieved in Q4. 
- **Customer Pricing**: Maintain premium pricing despite virgin PP volatility. Churchill sees no pushback on premium resin costs. 
- ** Augusta Timeline**: Civil work underway, long-lead equipment secured. EU and Asian expansion discussions active. 
- **Feedstock Flexibility**: Running 99% PCR, with ability to shift to PIR if needed. Denver facility reduces net feedstock costs. 
- ** Automotive Regulatory Tailwinds**: Europe 25% recycled content mandate by 2030 creating $1B+ annual opportunity. 


PCT

PCT fundamentals

Earnings Call

You can ask Aime